TY - JOUR
T1 - Innovation cycles and geographies of innovation
T2 - A study of healthcare innovation in Europe
AU - Lawton Smith, Helen
AU - Bagchi-Sen, Sharmistha
AU - Edmunds, Laurel
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The research leading to these results has received funding from the EU’s Seventh Framework Programme (FP7/2007-2013) under Grant Agreement No 26555.
Funding Information:
All areas have activity in the medical technology, medical biotechnology, industrial biotechnology and pharmaceutical sectors, but the South East (Thames Valley, Oxfordshire), the East of England (Cambridgeshire) and London together contain 60% of all employment.20 In OTV, Oxford and particularly Oxford University dominate. Its translational trajectory is predicated on its very strong science base, much of which is funded by national and international research funding bodies (research councils, national charities and currently the EU). The main local sector Network and the LSZ Business Network, have been network is OBN,21 a membership organisation with initiated. some 400 member companies, which has spread its activities beyond Oxfordshire, providing networking, partnership, purchasing and training activities. OBN in practise is not a formal part of a locally organised innovation cycle, as is the case with Biocat.
Funding Information:
Switzerland operates ‘a systemic approach to research’.22As an established approach in Swiss politics, the division of tasks between the private and the public sector in the field of research and innovation is based on two pillars: the principle of subsidiarity and a liberal economy. Thus, the government becomes only active in areas where it is constitutionally authorised so to do. Under the Research and Innovation Promotion Act (RIPA), the Swiss government is responsible for providing grant funding for research and innovation through the Swiss National Science Foundation (SNSF) and the Commission for Technology and Innovation (CTI).23 The Federal budget through the SNSF and programmes such as the national centres of Competence in Research (NCCR) for university-based education, research and innovation, is very high.
Publisher Copyright:
© The Author(s) 2017.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - This paper examines place-specific factors affecting geographies of innovation, that is, the transfer of research from the laboratory to bedside in the healthcare sector in four European bioscience regions. These regions are Medical Delta (MD; Leiden, Rotterdam and Delft, Netherlands) Oxford and the Thames Valley (OTV; UK), Biocat (Catalonia, Spain) and Life Science Zurich (LSZ; Switzerland). Evidence is drawn from the European Union-funded Healthcare Technology and Innovation for Economic Success (HealthTIES) project (2010–2013). The analytical framework, the HealthTIES Innovation Cycle, is organised into resources (inputs), innovation system elements and outcomes. The paper shows that each region represents different positions within international value chains of innovation in the healthcare sector. They range from the highly research intensive but with relatively less in the way of commercial exploitation location (OTV) to the less research intensive but with more commercialisation (LSZ).
AB - This paper examines place-specific factors affecting geographies of innovation, that is, the transfer of research from the laboratory to bedside in the healthcare sector in four European bioscience regions. These regions are Medical Delta (MD; Leiden, Rotterdam and Delft, Netherlands) Oxford and the Thames Valley (OTV; UK), Biocat (Catalonia, Spain) and Life Science Zurich (LSZ; Switzerland). Evidence is drawn from the European Union-funded Healthcare Technology and Innovation for Economic Success (HealthTIES) project (2010–2013). The analytical framework, the HealthTIES Innovation Cycle, is organised into resources (inputs), innovation system elements and outcomes. The paper shows that each region represents different positions within international value chains of innovation in the healthcare sector. They range from the highly research intensive but with relatively less in the way of commercial exploitation location (OTV) to the less research intensive but with more commercialisation (LSZ).
KW - Healthcare
KW - innovation cycles
KW - innovation geographies
KW - public policy
KW - regional development
UR - http://www.scopus.com/inward/record.url?scp=85054860062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054860062&partnerID=8YFLogxK
U2 - 10.1177/0969776417716220
DO - 10.1177/0969776417716220
M3 - Article
AN - SCOPUS:85054860062
SN - 0969-7764
VL - 25
SP - 405
EP - 422
JO - European Urban and Regional Studies
JF - European Urban and Regional Studies
IS - 4
ER -